ArriVent BioPharma, Inc. (AVBP)
AVBPNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$13.49
-0.6700 (-4.73%) today
At the close, Nov 10, 4:00 PM ET. After hours $13.49 –
- Market cap
- $665.16m
- P/E
- –
- EPS, last 4 quarters
- $-3.60
- Dividend yield
- –
- Day range
- $13.21 to $15.05
- 52-week range
- $11.36 to $35.83
- Average volume
- 1.46m
- Previous close
- $14.16
Analysts
12 coveringBuy12 buy, 0 hold, 0 sell
Targets a year out average $26.09, +93.4% from here
Earnings
next estimate $-1.03Next report
Dec 2025
+10.3%
Mar 2026
-9.1%
Jun 2026
-7.1%
Sep 2026
+22.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$38.32m | -$38.82m | -$46.11m | -$52.69m |
| Net income | -$34.98m | -$35.54m | -$43.32m | -$49.89m |
News
8 latest- ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues RTTNews · 13 hours ago
- ArriVent BioPharma Announces Retirement of R&D President, Appointment of Priti Patel to Lead R&D, and Third Quarter 2026 Financial ResultsFintel · 1 day ago
- ArriVent BioPharma Consensus Price Target Increased 14.29% to $25.96Fintel · Nov 2, 2026
- ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer StudyMarketBeat · Oct 27, 2026
- ArriVent BioPharma, Inc. Announces Initial Phase 1 Data for CDH17-Targeted ADC ARR-217Fintel · Oct 26, 2026
- Biotech Stocks In Focus - SXTC +536% On Sharp Move; VRXA, AVBP, SPRC On Key Developments RTTNews · Oct 7, 2026
- Noteworthy Friday Option Activity: TYRA, CLYM, AVBPBNK Invest · Sep 4, 2026
- Notable Monday Option Activity: AVBP, SOC, HNRGBNK Invest · Jun 22, 2026
The company
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team's deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- arrivent.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.